Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 30:20:7021-7035.
doi: 10.2147/IJN.S523213. eCollection 2025.

Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics

Affiliations
Review

Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics

Tianzhu Wang et al. Int J Nanomedicine. .

Abstract

Nasopharyngeal carcinoma (NPC) remains a major clinical challenge due to its high resistance to conventional therapies such as chemotherapy and radiotherapy. Nanoparticle (NP)-based technologies have emerged as promising tools to enhance the efficacy of NPC treatment through mechanisms like radiosensitization and photothermal therapy. This review discusses the potential of NPs, particularly metal-based nanoparticles (gold and iron oxide), in improving the therapeutic outcomes of radiotherapy by overcoming tumor hypoxia and increasing radiation absorption. Additionally, we explore the application of NPs in photothermal therapy, wherein nanoparticles absorb light and generate localized heat to target tumor cells with precision. NPs are also playing an increasingly vital role in early diagnosis and real-time imaging, enabling more effective monitoring and personalized treatment. Despite the promising potential, challenges as nanoparticle biocompatibility, toxicity, and efficient targeting remain obstacles for clinical translation. In this review, we aim to provide a comprehensive summary of the current state of targeted nanoparticle-based interventions in NPC therapy and to outline the potential for these technologies to improve therapeutic outcomes.

Keywords: nanomedicine; nanoparticle; nanotechnology; nasopharyngeal carcinoma; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Characterization of Pt-HFn Structure and Catalase-Like Activity. (a) Left: TEM image of Pt-HFn with negative staining, highlighting the morphology of the HFn shell. Right: Particle size distribution of HFn derived from TEM analysis. Scale bar, 10 nm. (b) Left: TEM image of Pt-HFn without negative staining, revealing the morphology of the Pt core. Right: Size distribution of the Pt core from TEM analysis. Scale bar, 10 nm. (c) High-resolution TEM image of the Pt core within Pt-HFn, with insets showing atomic-level images of selected areas and their corresponding fast Fourier transform (FFT) patterns. Scale bar, 2 nm. (d) TEM-EDS spectrum of Pt-HFn, with the inset displaying the mass and atomic percentages of the elements present in the sample. (e) Upper: Diagram illustrating the catalase-like activity of Pt-HFn in decomposing H2O2 to produce O2. Lower: Photographs showing the generation of O2 bubbles in H2O2 solutions for each group. (f) Absorbance changes at 240 nm, indicating H2O2 reduction in solutions for each group (n = 4 independent experiments). (g) Changes in dissolved oxygen levels demonstrate increased O2 content in H2O2 solutions for each group (n = 3 independent experiments). Data are presented as mean ± SEM. Reproduced from Zhang R, Shen Y, Zhou X, et al. Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization. Nat Commun. 2025;16(1):890. Copyright © 2025, The Author(s). This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 2
Figure 2
Schematic diagrams of α-NTP and α-NTP-LNs illustrate the targeting mechanism. α-NTP-LNs were shown to specifically target NPC, demonstrating the combined synergistic effect of the α-peptide and NTP within the α-NTP fusion peptide for enhanced targeting. Reproduced from Luo H, Lu L, Yang F, et al. Nasopharyngeal cancer-specific therapy based on fusion peptide-functionalized lipid nanoparticles. ACS Nano. 2014;8(5):4334–4347. Copyright 2014, American Chemical Society.
Figure 3
Figure 3
Enhancement of Radiosensitivity in NPC Using Fe@Pdots-siRNA Nanomaterials. (A) Schematic illustration of the synthesis process for nanomaterials, which are encapsulated in NPC cell membrane cores composed of iron-doped semiconducting polymer nanoparticles (Fe@Pdot). These nanoparticles carry siRNA targeting circADARB1 or a scrambled siRNA as a negative control (NC), referred to as Fe@Pdots-siRNA and Fe@Pdots-siNC, respectively. (B) Representative transmission electron microscopy (TEM) images of Pdots, Fe@Pdots, Fe@Pdots-siNC, and Fe@Pdots-siRNA. (C) Particle size distribution of the four iron-loaded nanomaterials: Pdots, Fe@Pdots, Fe@Pdots-siNC, and Fe@Pdots-siRNA. (D) Fourier-transform infrared (FTIR) spectroscopy analysis of the chemical composition and molecular structure of the four nanomaterials. (E) In vivo fluorescence imaging was performed on tumor-bearing nude mice intravenously injected with saline, Fe@Pdots, Fe@Pdots-siNC, or Fe@Pdots-siRNA (10 mg/kg body weight). Imaging was conducted at 0, 6, 12, and 24 hours post-injection to track the distribution and accumulation of the nanomaterials in tumor tissues. The yellow circles represent the sites of tumor inoculation. (F) After 12 hours, the mice were euthanized, and organs including the heart, liver, spleen, lungs, kidneys, and tumor tissues were collected. The biodistribution of the nanomaterials in these organs and NPC xenografts was further assessed through in vivo imaging. (G) To establish a tumor-bearing model, nude mice were subcutaneously injected with NPC cells (CNE2) into the right dorsal flank. After 14 days, when xenografts reached 100–150 mm³, mice were randomly divided into three groups (n = 12). On days 14 and 20, each group received intravenous injections of saline, Fe@Pdots-siNC, or Fe@Pdots-siRNA (10 mg/kg body weight). Half of the mice in each group (n = 6) received 6 Gy X-ray irradiation at the tumor site (IR). Tumor sizes were measured every 3 days, and mice were euthanized on day 29. (H) At the end of the study, xenograft tumors were excised, and their volumes and weights were measured. **p < 0.01, ****p < 0.0001. Reproduced from Wang D, Tang L, Chen M, et al. Nanocarriers targeting circular RNA ADARB1 boost radiosensitivity of nasopharyngeal carcinoma through synergically promoting ferroptosis. ACS Nano. 2024;18(45):31055–31075.. Copyright 2024, American Chemical Society.
Figure 4
Figure 4
Characterization of USPIO-PEG-sLex nanoparticles. (A) Transmission electron microscopy (TEM) image of USPIO-PEG-sLex nanoparticles, revealing predominantly square and polygonal shapes, with a few spherical particles. (B) Particle size distribution of USPIO-PEG and USPIO-PEG-sLex. (C) Zeta potential measurements of USPIO-PEG (a) and USPIO-PEG-sLex (b). (D) Fourier-transform infrared (FTIR) spectra of USPIO-PEG and USPIO-PEG-sLex. Reproduced from Liu Q, Liu L, Mo C, et al. Polyethylene glycol-coated ultrasmall superparamagnetic iron oxide nanoparticles-coupled sialyl Lewis X nanotheranostic platform for nasopharyngeal carcinoma imaging and photothermal therapy. J Nanobiotechnology. 2021;19(1):171. © The Author(s) 2021. Creative Commons Attribution 4.0 International License.

Similar articles

References

    1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0 - DOI - PubMed
    1. Lee AWM, Ng WT, Chan JYW, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79:101890. doi:10.1016/j.ctrv.2019.101890 - DOI - PubMed
    1. Su ZY, Siak PY, Lwin YY, Cheah SC. Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 2024;43(3):919–939. doi:10.1007/s10555-024-10176-9 - DOI - PubMed
    1. Bossi P, Chan AT, Licitra L, et al; E.G.C.E.a. clinicalguidelines@esmo.org, Euracan. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32(4):452–465. doi:10.1016/j.annonc.2020.12.007 - DOI - PubMed
    1. Bossi P, Gurizzan C, Chan A. Immunotherapy for nasopharyngeal carcinoma: the earlier the better. JAMA. 2023;330(20):1954–1955. doi:10.1001/jama.2023.22465 - DOI - PubMed

MeSH terms

LinkOut - more resources